《大行報告》美銀證券首予固生堂(02273.HK)「買入」評級 目標價57.8元
美銀證券發表報告,首予固生堂(02273.HK)「買入」評級,目標價57.8元。
報告指,固生堂是中國領先的中醫保健服務提供者,通過線下醫療機構和在線保健平臺,爲客戶提供全面的中醫保健服務和產品。根據Frost & Sullivan的數據,在中國的私營中醫保健服務提供商中,在2020年固生堂在提供保健解決方案的收入方面排名第八。
該行提到,醫療保健解決方案部門在2020年貢獻固生堂總收入96.4%,預計該板塊在2021至2023年將分別實現12.93億元人民幣(下同)/18.1億元/24.98億元收入,推動總收入在2021年至23年分別達到13.32億元/18.55億元/25.49億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.